{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T02:52:30Z","timestamp":1771901550164,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.vaccine.2020.02.018","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T23:12:22Z","timestamp":1582067542000},"page":"2833-2840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Japanese encephalitis vaccination in the Philippines: A cost-effectiveness analysis comparing alternative delivery strategies"],"prefix":"10.1016","volume":"38","author":[{"given":"Elisabeth","family":"Vodicka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marita","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Lena","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Wilda","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonita","family":"Gorgolon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toda","family":"Kohei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Mooney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzana","family":"Muhib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clint","family":"Pecenka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony A.","family":"Marfin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.02.018_b0005","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.vaccine.2015.07.057","article-title":"WHO position paper, February 2015 - Recommendations","volume":"34","author":"Japanese Encephalitis Vaccines","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.018_b0010","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.68.4.405","article-title":"Japanese encephalitis","volume":"68","author":"Solomon","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.vaccine.2020.02.018_b0015","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.4161\/21645515.2014.980197","article-title":"Immunogenicity and safety of currently available Japanese encephalitis vaccines: A systematic review","volume":"10","author":"Li","year":"2014","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2020.02.018_b0020","unstructured":"PATH. Safety of CD-JEV: A proven tool for JE prevention; 2018. https:\/\/path.azureedge.net\/media\/documents\/CVIA_Safety_CD_JEV_fs.pdf [accessed January 20, 2019]."},{"key":"10.1016\/j.vaccine.2020.02.018_b0025","article-title":"Information sheet observed rate of vaccine reactions - Japanese encephalitis vaccine","author":"WHO","year":"2016","journal-title":"Inf Sheet"},{"key":"10.1016\/j.vaccine.2020.02.018_b0030","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2471\/BLT.10.085233","article-title":"Estimated global incidence of Japanese encephalitis: a systematic review","volume":"89","author":"Campbell","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2020.02.018_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0264-410X(00)00037-2","article-title":"New initiatives for the control of Japanese encephalitis by vaccination","volume":"18","author":"Tsai","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.018_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003630","article-title":"Epidemiology of Japanese encephalitis in the Philippines: a systematic review","volume":"9","author":"Lopez","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.02.018_b0045","unstructured":"Republic of the Philippines Department of Health. Japanese Encephalitis Monthly Surveillance Report No. 12; 2018."},{"key":"10.1016\/j.vaccine.2020.02.018_b0050","doi-asserted-by":"crossref","first-page":"579","DOI":"10.15585\/mmwr.mm6622a3","article-title":"Japanese encephalitis surveillance and immunization \u2014 Asia and Western Pacific Regions, 2016","volume":"66","author":"Heffelfinger","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2020.02.018_b0055","unstructured":"Life tables by country - Philippines. World Health Organization. Global Health Observatory Data Repository; 2015. http:\/\/apps.who.int\/gho\/data\/view.main.LT62150?lang=en [accessed March 1, 2017]."},{"key":"10.1016\/j.vaccine.2020.02.018_b0060","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1016\/S2214-109X(15)00069-8","article-title":"Disability weights for the Global Burden of Disease 2013 study","volume":"3","author":"Salomon","year":"2015","journal-title":"Lancet Glob Heal"},{"key":"10.1016\/j.vaccine.2020.02.018_b0065","unstructured":"The World Bank. Birth rate, crude (per 1000 people). Data from Database Popul Estim Proj Last Updat Sept 20, 2018 Available Online Http\/\/DatabankWorldbankOrg\/Data\/Source\/Population-Estimates-and-Projections# [last accessed Novemb 12, 2018 n.d.]."},{"key":"10.1016\/j.vaccine.2020.02.018_b0070","unstructured":"Philippine Statistics Authority, 2015 Census of Population. Accessed online at: http:\/\/psa.gov.ph\/content\/highlights-philippine-population-2015-census-population. n.d."},{"key":"10.1016\/j.vaccine.2020.02.018_b0075","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA - J Am Med Assoc"},{"key":"10.1016\/j.vaccine.2020.02.018_b0080","unstructured":"Department of Health Internal Report; unpublished. MCV1 Vaccine Coverage, Philippines. 2015."},{"key":"10.1016\/j.vaccine.2020.02.018_b0085","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-10-253","article-title":"Health and economic impact of rotavirus vaccination in GAVI-eligible countries","volume":"10","author":"Kim","year":"2010","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2020.02.018_b0090","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1016\/j.vaccine.2008.06.050","article-title":"Cost-effectiveness of Japanese encephalitis (JE) immunization in Bali, Indonesia","volume":"26","author":"Liu","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.018_b0095","unstructured":"The World Bank. \u201cGDP per Capita.\u201d https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD [accessed April 30, 2018. n.d.]."},{"key":"10.1016\/j.vaccine.2020.02.018_b0100","unstructured":"World Economic Outlook Data (IMF; Oct 2017); https:\/\/www.exchange-rates.org\/history\/PHP\/USD\/T n.d."},{"key":"10.1016\/j.vaccine.2020.02.018_b0105","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2471\/BLT.15.164418","article-title":"Cost\u2013effectiveness thresholds: pros and cons","volume":"94","author":"Bertram","year":"2016","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2020.02.018_b0110","doi-asserted-by":"crossref","unstructured":"Hutubessy R, Chisholm D, Edejer TT-T, WHO-CHOICE. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc 2003;1:8. doi:10.1186\/1478-7547-1-8.","DOI":"10.1186\/1478-7547-1-8"},{"key":"10.1016\/j.vaccine.2020.02.018_b0115","series-title":"World development report 1993: Investing in health","author":"World Bank","year":"1993"},{"key":"10.1016\/j.vaccine.2020.02.018_b0120","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jval.2017.12.016","article-title":"Use and misuse of cost-effectiveness analysis thresholds in low- and middle-income countries: trends in cost-per-DALY studies","volume":"21","author":"Leech","year":"2018","journal-title":"Value Heal"},{"key":"10.1016\/j.vaccine.2020.02.018_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002397","article-title":"When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs","volume":"14","author":"Bilinski","year":"2017","journal-title":"PLOS Med"},{"key":"10.1016\/j.vaccine.2020.02.018_b0130","first-page":"334","article-title":"Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China","volume":"81","author":"Ding","year":"2003","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2020.02.018_b0135","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1016\/j.vaccine.2012.05.068","article-title":"An economic evaluation of the use of Japanese encephalitis vaccine in the expanded program of immunization of Guizhou province, China","volume":"30","author":"Yin","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.018_b0140","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1016\/j.vaccine.2010.04.086","article-title":"A cost\u2013effectiveness analysis of Japanese encephalitis vaccine in Cambodia","volume":"28","author":"Touch","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.018_b0145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1524-4733.2009.00660.x","article-title":"Good research practices for measuring drug costs in cost-effectiveness analyses: A societal perspective. The ISPOR drug cost task force report - Part II","volume":"13","author":"Garrison","year":"2010","journal-title":"Value Heal"},{"issue":"e0131156","key":"10.1016\/j.vaccine.2020.02.018_bib146","article-title":"Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.","volume":"10","author":"Haasis","year":"2015","journal-title":"PLoS One"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2030205X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2030205X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:40:39Z","timestamp":1759401639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2030205X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":30,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0264410X2030205X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.018","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Japanese encephalitis vaccination in the Philippines: A cost-effectiveness analysis comparing alternative delivery strategies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}